Effects of early spasticity treatment on children with hemiplegic cerebral palsy: a preliminary study

Area of Science:

• Neurology
• Pediatrics
• Rehabilitation Medicine

Background:

• Hemiplegic cerebral palsy (HCP) presents significant motor and functional challenges in children.
• Spasticity is a common and debilitating symptom in HCP, impacting development.
• Early intervention strategies are crucial for optimizing outcomes in children with HCP.

Purpose of the Study:

• To compare the motor and functional performance of children with HCP receiving early botulinum neurotoxin type A (BXT-A) treatment versus a control group.
• To evaluate the efficacy of BXT-A in managing spasticity and its impact on developmental milestones.

Main Methods:

• Two groups of children with HCP were assessed.
• The study group (SG) received early spasticity treatment with BXT-A.
• Performance was measured using the Gross Motor Function Measure (GMFM) and Pediatric Evaluation of Disability Inventory (PEDI), alongside range of movement, gait analysis (Physician Rating Scale - PRS), and hand movement speed.

Main Results:

• The SG demonstrated higher scores across most GMFM dimensions (statistically significant in dimension B) and PEDI areas compared to the control group.
• Improvements were noted in active wrist extension and hand movement speed in the SG.
• The Physician Rating Scale (PRS) score also indicated better gait patterns in the SG.

Conclusions:

• Early intervention with BXT-A for spasticity in children with HCP leads to enhanced motor and functional performance.
• BXT-A treatment is a valuable therapeutic option for improving developmental outcomes in pediatric HCP.
• This study supports the benefits of timely management of spasticity in hemiplegic cerebral palsy.